Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
暂无分享,去创建一个
M. Hallek | C. Wendtner | M. Kneba | M. Ritgen | C. Schweighofer | R. Busch | B. Eichhorst | W. Abenhardt